Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Symmetry Medical acquires DePuy Orthopaedic instrument facility
In December 2007, Symmetry and DePuy have entered into a supply agreement which requires DePuy to make minimum purchases from the New Bedford facility for a four year
In December 2007, Symmetry and DePuy have entered into a supply agreement which requires DePuy to make minimum purchases from the New Bedford facility for a four year
The lawsuit is in response to Impax’s notice to Endo and Penwest, announced on December 17, 2007, advising of the FDA’s acceptance for substantive review, as of November
In December, 2007 BioMS Medical has entered into a global licensing and development agreement granting Lilly exclusive worldwide rights to BioMS Medical’s lead drug, MBP8298, for the treatment
The clinical study will be a first-in-man Phase I, randomized, placebo controlled, dose-escalation, single center study in which the safety and tolerability of escalating doses of AZX100 will
Lace’s Glaid is a revolutionary diagnostic device that utilizes Pattern Electroretinogram (PERG) to provide a visual stimulus that generates electrical responses of the retina to measure the physical
The trial, designed as a safety study, successfully showed that BrachySil, in combination with standard chemotherapy (gemcitabine), was well tolerated with no clinically significant adverse events related to
The study will evaluate the efficacy of WX-671 in combination with the chemotherapeutic agent capecitabine (Xeloda) in patients with HER2-receptor negative metastatic breast cancer. The trial is supported
The newly granted patent includes 32 claims broadly covering compositions and methods, including pharmaceutical compositions, for small interfering RNAs (siRNAs), the molecules that mediate RNAi. The claims cover
Under an International Innovation Subsidy granted by SenterNovem, an agency of the Dutch Ministry of Economic Affairs, DNage has initiated a project with the Eberhard Karls University in
This new broader label will now allow Avastin to be used in combination with any chemotherapy, including Roche’s oral chemotherapy Xeloda (capecitabine), for 1st and later treatment lines